Wang Keqiang, Xiu Meihong, Su Xiuru, Wu Fengchun, Zhang Xiangyang
Hebei Province Veterans Hospital, Baoding 071000, China.
Beijing HuiLongGuan Hospital, HuiLongGuan Clinical Medical School, Peking University, Beijing 100096, China.
Antioxidants (Basel). 2022 Mar 28;11(4):646. doi: 10.3390/antiox11040646.
Schizophrenia (SCZ) is associated with aberrant redox regulation in the early stages of brain development. There is growing evidence that the antioxidant defense system is closely associated with the therapeutic response to antipsychotics in SCZ patients. The aim of this study was to examine the effect of risperidone monotherapy on total antioxidant status (TAS) and the relationship between symptom improvement and changes in TAS in patients with antipsychotic-naïve first-episode (ANFE) SCZ. Clinical symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS). Two hundred and forty-six ANFE patients were treated with risperidone for 3 months. PANSS and TAS levels were assessed at baseline and at a 3-month follow-up. Relative to healthy controls, ANFE patients had higher TAS levels, which increased even further during the treatment. Moreover, baseline TAS levels were a predictor of symptom reduction after risperidone treatment. In addition, there was a significant association between increased TAS levels and the decreased cognitive factor. Our findings suggest that antioxidant protection is possibly associated with clinical improvement in ANFE patients after risperidone treatment.
精神分裂症（SCZ）与大脑发育早期异常的氧化还原调节有关。越来越多的证据表明，抗氧化防御系统与SCZ患者对抗精神病药物的治疗反应密切相关。本研究的目的是探讨利培酮单药治疗对初发未使用过抗精神病药物的首发（ANFE）SCZ患者总抗氧化状态（TAS）的影响，以及症状改善与TAS变化之间的关系。使用阳性和阴性症状量表（PANSS）评估临床症状。246例ANFE患者接受利培酮治疗3个月。在基线和3个月随访时评估PANSS和TAS水平。与健康对照相比，ANFE患者的TAS水平更高，治疗期间进一步升高。此外，基线TAS水平是利培酮治疗后症状减轻的预测指标。此外，TAS水平升高与认知因子降低之间存在显著关联。我们的研究结果表明，抗氧化保护可能与利培酮治疗后ANFE患者的临床改善有关。
